US20130052215A9 - Tumor vaccine - Google Patents

Tumor vaccine Download PDF

Info

Publication number
US20130052215A9
US20130052215A9 US12/580,554 US58055409A US2013052215A9 US 20130052215 A9 US20130052215 A9 US 20130052215A9 US 58055409 A US58055409 A US 58055409A US 2013052215 A9 US2013052215 A9 US 2013052215A9
Authority
US
United States
Prior art keywords
hla
patients
cells
tumor
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/580,554
Other languages
English (en)
Other versions
US20100119537A1 (en
Inventor
Eckhard Podack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/950,157 external-priority patent/US20090162404A1/en
Application filed by University of Miami filed Critical University of Miami
Priority to US12/580,554 priority Critical patent/US20130052215A9/en
Publication of US20100119537A1 publication Critical patent/US20100119537A1/en
Assigned to UNIVERSITY OF MIAMI reassignment UNIVERSITY OF MIAMI ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PODACK, ECKHARD
Publication of US20130052215A9 publication Critical patent/US20130052215A9/en
Priority to US14/812,416 priority patent/US10279020B2/en
Priority to US16/286,086 priority patent/US20190175706A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung

Definitions

  • FIG. 6 illustrates the sequence and annotation of one embodiment of a BPV-1-B7.1-HLA A1 vector.
  • An exemplary allogeneic tumor cell is the AD 100 cell line, which is a human lung adenocarcinoma cell line, as disclosed herein.
  • Other lung cancer cell lines are well known to those skilled in the art and can be similarly used to generate an allogeneic cell genetically modified with CD80 (B7.1) and an HLA antigen.
  • numerous cell lines, including lung cancer cell lines are well known and available from the American Type Culture Collection (ATCC; Manassas Va.).
  • HLA A1 positive patients received the AD-A1-B7 vaccine; HLA A2 positive patients received the AD-A2-B7 vaccine; and patients that were neither HLA A1 nor A2 positive received either the AD-A1-B7 or AD-A2-B7 vaccine.
  • the frequency of IFN-y secreting CD8 cells was determined by ELISPOT after restimulation of purified patient-CD8 cells in vitro with HLA A1 or A2 transfected or untransfected AD100. Controls included stimulation with K562 and incubation of CD8 cells without stimulator cells.
  • Table 2 shows a summary of clinical responses, immunological CD8 responses, survival and pretreatment of fifteen patients with advanced stage IIIB/IV NSCLC treated with allogeneic B7/HLA A transfected NSCLC vaccine.
  • the abbreviations in Table 2 are: PD—progressive disease; NE—not evaluable for immune response, but included in survival analysis on the right; PR—partial response; SD-sable disease; C—chemotherapy; R—radiation; S—surgery. Survival indicates time of survival since study entry; +indicates patient alive; n. d. no done, patients off study because of progression.
  • Example 2 This example describes a continuation of the study described in Example 2, including additional patients and time of study. Experiments were performed essentially as described in Example 2 and Raez et al., J. Clin. Oncol. 22: 2800-2807 (2004).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US12/580,554 2003-09-26 2009-10-16 Tumor vaccine Abandoned US20130052215A9 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/580,554 US20130052215A9 (en) 2003-09-26 2009-10-16 Tumor vaccine
US14/812,416 US10279020B2 (en) 2003-09-26 2015-07-29 Tumor vaccine
US16/286,086 US20190175706A1 (en) 2003-09-26 2019-02-26 Tumor vaccine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50665603P 2003-09-26 2003-09-26
US10/950,157 US20090162404A1 (en) 2003-09-26 2004-09-24 Tumor vaccine
US10635508P 2008-10-17 2008-10-17
US12/580,554 US20130052215A9 (en) 2003-09-26 2009-10-16 Tumor vaccine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/950,157 Continuation-In-Part US20090162404A1 (en) 2003-09-26 2004-09-24 Tumor vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/812,416 Continuation US10279020B2 (en) 2003-09-26 2015-07-29 Tumor vaccine

Publications (2)

Publication Number Publication Date
US20100119537A1 US20100119537A1 (en) 2010-05-13
US20130052215A9 true US20130052215A9 (en) 2013-02-28

Family

ID=42107278

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/580,554 Abandoned US20130052215A9 (en) 2003-09-26 2009-10-16 Tumor vaccine
US14/812,416 Active 2025-03-08 US10279020B2 (en) 2003-09-26 2015-07-29 Tumor vaccine
US16/286,086 Abandoned US20190175706A1 (en) 2003-09-26 2019-02-26 Tumor vaccine

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/812,416 Active 2025-03-08 US10279020B2 (en) 2003-09-26 2015-07-29 Tumor vaccine
US16/286,086 Abandoned US20190175706A1 (en) 2003-09-26 2019-02-26 Tumor vaccine

Country Status (6)

Country Link
US (3) US20130052215A9 (fr)
EP (1) EP2346531A4 (fr)
JP (3) JP2012505918A (fr)
AU (1) AU2009305617B2 (fr)
CA (1) CA2740779A1 (fr)
WO (1) WO2010045573A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11369668B1 (en) 2019-12-03 2022-06-28 Neuvogen, Inc. Tumor cell vaccines
US11559574B2 (en) 2016-02-25 2023-01-24 Briacell Therapeutics Corp. Whole-cell cancer vaccines and methods for selection thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740779A1 (fr) * 2008-10-17 2010-04-22 University Of Miami Vaccin antitumoral
AU2011316986A1 (en) * 2010-10-20 2013-06-06 Rush University Medical Center Lung cancer tests
WO2012156969A1 (fr) 2011-05-17 2012-11-22 Hadasit Medical Research Services And Development Ltd. Vaccination par des cellules tumorales allogéniques
US9753037B2 (en) 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
EP3080299B1 (fr) 2013-12-09 2020-09-30 Rush University Medical Center Biomarqueurs de progression rapide du cancer du poumon non à petites cellules à un stade avancé
WO2018071405A1 (fr) * 2016-10-11 2018-04-19 University Of Miami Vecteurs et cellules de vaccin pour immunité contre le virus zika
WO2020076568A1 (fr) * 2018-10-10 2020-04-16 University Of Miami Procédés et compositions pour le traitement du cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069941A (en) * 1960-01-06 1962-12-25 Elastic Stop Nut Corp Screw threading tool
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
US6723705B1 (en) * 1993-08-19 2004-04-20 Gentics Institute, Inc. Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US6218510B1 (en) * 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
DE4431401A1 (de) 1994-08-24 1996-02-29 Max Delbrueck Centrum Lebendvakzine gegen Tumorerkrankungen
GB9620350D0 (en) * 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
US6503503B1 (en) * 1997-05-13 2003-01-07 Duke University Allogeneic cellular vaccine
US6716823B1 (en) * 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
JP2007506764A (ja) * 2003-09-26 2007-03-22 ユニバーシティ オブ マイアミ 腫瘍ワクチン
AU2004290866B2 (en) * 2003-11-19 2010-09-02 Survac Aps Proteins belonging to the BcL-2 family and fragments thereof, and their use in cancer patients
WO2008027456A2 (fr) * 2006-08-31 2008-03-06 The Trustees Of The University Of Pennsylvania Procédés, compositions et ensembles concernant des cellules tumorales présentant des antigènes
CA2740779A1 (fr) * 2008-10-17 2010-04-22 University Of Miami Vaccin antitumoral

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Matthias et al. (EMBO, 1983, Vol. 2, p. 1487-1492). *
Padmanabhan et al. (Proceedings of the American Association for Cancer Research, March 2002, Vol. 43, page 557). *
Raez et al. (Journal of Clinical Oncology, July 2004, Vol. 22, p. 2800-2807) *
Yamazaki et al. (Cancer Research, 1999, Vol. 59, p. 4642-4650 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11559574B2 (en) 2016-02-25 2023-01-24 Briacell Therapeutics Corp. Whole-cell cancer vaccines and methods for selection thereof
US11369668B1 (en) 2019-12-03 2022-06-28 Neuvogen, Inc. Tumor cell vaccines
US11684659B2 (en) 2019-12-03 2023-06-27 Neuvogen, Inc. Tumor cell vaccines

Also Published As

Publication number Publication date
US20100119537A1 (en) 2010-05-13
CA2740779A1 (fr) 2010-04-22
US20190175706A1 (en) 2019-06-13
US20160045583A1 (en) 2016-02-18
US10279020B2 (en) 2019-05-07
JP2012505918A (ja) 2012-03-08
JP2016128445A (ja) 2016-07-14
EP2346531A2 (fr) 2011-07-27
WO2010045573A2 (fr) 2010-04-22
JP2014040429A (ja) 2014-03-06
AU2009305617B2 (en) 2014-01-23
EP2346531A4 (fr) 2013-07-17
WO2010045573A3 (fr) 2010-07-08
AU2009305617A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
US20190175706A1 (en) Tumor vaccine
EP2246067B1 (fr) Procédés destinés à susciter, améliorer et entretenir les réponses immunitaires contre des épitopes limités au CMH de classe I dans des buts prophylactiques ou thérapeutiques
Eager et al. GM-CSF gene-transduced tumor vaccines
Gulley et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer
AU2010200003B2 (en) Tumor vaccine
AU2005321904B2 (en) Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
Saenz‐Badillos et al. RNA as a tumor vaccine: a review of the literature
JP2001517206A (ja) 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
Galili Autologous tumor vaccines processed to express α-gal epitopes: a practical approach to immunotherapy in cancer
CN101020064A (zh) 一种布鲁氏杆菌核酸疫苗
Bonnekoh et al. Immunological gene therapy approaches for malignant melanoma: 2. Preclinical Studies and Clinical Strategies
Kim et al. Prolongation of the survival of breast cancer-bearing mice immunized with GM-CSF-secreting syngeneic/allogeneic fibroblasts transfected with a cDNA expression library from breast cancer cells
Dallal et al. Immunotherapy of metastasis
AU2011213698B2 (en) Method to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
US20030157059A1 (en) Feline interleukin-12 as immunostimulant
Schott et al. Immunotherapy of Neuroendocrine Tumors

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITY OF MIAMI, FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PODACK, ECKHARD;REEL/FRAME:025596/0270

Effective date: 20091202

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION